Capricor Therapeutics (NASDAQ:CAPR) Rating Reiterated by HC Wainwright

Capricor Therapeutics (NASDAQ:CAPR)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research report issued to clients and investors on Tuesday, Benzinga reports. They currently have a $40.00 price target on the biotechnology company’s stock.

Capricor Therapeutics Trading Up 12.5 %

Capricor Therapeutics stock traded up $0.55 during midday trading on Tuesday, hitting $4.96. 859,169 shares of the stock were exchanged, compared to its average volume of 341,114. Capricor Therapeutics has a fifty-two week low of $2.68 and a fifty-two week high of $7.28. The stock has a market capitalization of $158.62 million, a price-to-earnings ratio of -5.72 and a beta of 3.92. The stock’s 50-day simple moving average is $4.33 and its 200 day simple moving average is $5.17.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. The company had revenue of $3.97 million for the quarter, compared to analysts’ expectations of $4.51 million. Equities analysts anticipate that Capricor Therapeutics will post -1.24 EPS for the current fiscal year.

Institutional Investors Weigh In On Capricor Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in shares of Capricor Therapeutics by 17.2% in the 1st quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock valued at $9,274,000 after acquiring an additional 200,499 shares during the last quarter. Renaissance Technologies LLC increased its stake in Capricor Therapeutics by 158.7% in the second quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock valued at $656,000 after purchasing an additional 84,350 shares during the period. Marshall Wace LLP acquired a new stake in shares of Capricor Therapeutics during the second quarter worth about $426,000. Bank of New York Mellon Corp lifted its position in Capricor Therapeutics by 12.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock worth $381,000 after acquiring an additional 9,040 shares during the period. Finally, Jump Financial LLC acquired a new stake in shares of Capricor Therapeutics during the fourth quarter worth $258,000. 21.68% of the stock is currently owned by institutional investors and hedge funds.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.